Literature DB >> 24093516

Trends in quality of care among patients with incident heart failure in Denmark 2003-2010: a nationwide cohort study.

Anne Nakano1, Søren Paaske Johnsen, Birgitte Lidegaard Frederiksen, Marie Louise Svendsen, Carsten Agger, Inge Schjødt, Kenneth Egstrup.   

Abstract

BACKGROUND: The treatment of heart failure (HF) is complex and the prognosis remains serious. A range of strategies is used across health care systems to improve the quality of care for HF patients. We present results from a nationwide multidisciplinary initiative to monitor and improve the quality of care and clinical outcome of HF patients using indicator monitoring combined with systematic auditing.
METHODS: We conducted a nationwide, population-based prospective study using data from the Danish Heart Failure Registry. The registry systematically monitors and audits the use of guideline recommended processes of care at Danish hospital departments treating incident HF patients. We identified patients registered between 2003 and 2010 (n = 24,504) and examined changes in use of recommended processes of care and 1-year mortality.
RESULTS: The use of the majority of the recommended processes of care increased substantially from 2003 to 2010: echocardiography (from 62.7% to 90.5%; Relative Risk (RR) 1.45 (95% CI, 1.39-1.50)), New York Heart Association classification (from 29.4% to 85.5%; RR 2.91 (95% CI, 2.69-3.14)), betablockers (from 72.6% to 88.3%; RR 1.23 (95% CI, 1.15-1.29)), physical training (from 5.6% to 22.8%; RR 4.04 (95% CI, 2.96-4.52)), and patient education (from 49.3% to 81.4%; RR 1.65 (95% CI, 1.52-1.80)). Use of ACE/ATII inhibitors remained stable (from 92.0% to 93.2%; RR 1.01 (95% CI, 0.99-1.04)). During the same period, 1-year mortality dropped from 20.5% to 12.8% (adjusted Hazard Ratio 0.79 (95% CI, 0.65-0.96).
CONCLUSIONS: Use of guideline recommended processes of care has improved among patients with incident HF included in the Danish Heart Failure Registry between 2003 and 2010. During the same period, a decrease in mortality was observed.

Entities:  

Mesh:

Year:  2013        PMID: 24093516      PMCID: PMC3851278          DOI: 10.1186/1472-6963-13-391

Source DB:  PubMed          Journal:  BMC Health Serv Res        ISSN: 1472-6963            Impact factor:   2.655


Background

Heart failure (HF) is an important cause of morbidity and mortality worldwide [1]. The prevalence of HF is increasing globally due to ageing populations in the developed countries, improved survival in patients suffering from coronary events and the success achieved in postponing coronary events using effective preventive measures [2-8]. HF care has developed substantially in recent decades and clinical trials have established several new therapies which have improved clinical outcomes for patients with HF and reduced left ventricular ejection fraction (LVEF) [8]. However, treatment guidelines are adopted slowly and applied inconsistently and may thus not result in the expected improvements in patient care and clinical outcomes [9-12]. Consequently, in many health care systems, major efforts are made to implement recommended guidelines [13]. However, population-based data on the implementation of the recommendations in everyday clinical practice and the possible impact on patient outcomes are still sparse [14]. In Denmark, the quality of care for patients with incident HF has been monitored and audited continuously in a national multidisciplinary quality improvement program since 2003. We aimed to examine whether the quality of care and the mortality among incident HF patients hospitalized in Denmark has changed following the introduction of the program.

Methods

The Danish heart failure registry

All Danish residents (approximately 5.5 million) have free access to hospital care provided by the tax-financed Danish National Health Service. The Danish Heart Failure Registry (DHFR) was established as a part of a larger nationwide initiative, The Danish National Indicator Project, in 2003 in order to monitor and improve the quality of care for HF patients [15]. Since 2003, the DHFR has monitored and supported implementation of evidence-based treatment and care for incident hospitalized HF patients. Participation is mandatory for all hospital units and outpatient cardiology clinics treating patients with HF. However, not all hospitals were able to report to the register when it was launched in 2003. The prognostic factors recorded in the registry as well as the evidence-based quality of care indicators were identified by a multidisciplinary national expert panel based on national [15] and international guidelines from the American College of Cardiology, the American Heart Association [16], and the European Society of Cardiology [17], supplemented by a systematic literature review. The expert panel followed a structured, rigorous and evidence-based guideline-driven process to develop pathways and tools for clinicians in hospitals and outpatient HF clinics in order to ensure data accuracy by standardizing procedures. This included developing detailed instructions for the data collection with strict data definitions ensuring that clinicians register data in the same manner at every hospital, as well as providing regular performance reports to the participating hospitals as also done in the American Heart Association Get With the Guidelines Program for Heart Failure [18]. The feasibility of collecting the required data in routine clinical settings, and the ability of the processes to reflect the multidisciplinary efforts involved in modern HF care, were also considered. The expert panel identified 6 process indicators and 1 outcome indicator (Table 1), and a number of prognostic factors (Table 2).
Table 1

Processes of care monitored in the Danish heart failure registry

Processes of care 
Echocardiography
Proportion of patients who undergo echocardiography
NYHA classification
Proportion of patients who undergo NYHA classification
Medication (ACE/ATII inhibitors)
Proportion of patients with reduced systolic function (LVEF below 40%) who is treated with ACE/ATII inhibitors
Medication (Betablockers)
Proportion of patients with reduced systolic function (LVEF below 40%) who is treated with betablockers
Physical training
Proportion of patients with reduced systolic function (LVEF below 40%) referred to individual physical training
Patient education
Proportion of patients with reduced systolic function (LVEF below 40%) who started a structured patient education (inclusive nutrition, physical training, understanding medical treatment, risk factors and symptoms of the disease)
1-year mortalityProportion of patients who die within one year of admission to a hospital or first outpatient contact

NYHA New York Heart Association, ACEI/ATII Angiotensin Converting Enzyme/Angiotensin II Antagonist inhibitors, LVEF Left Ventricular Ejection Fraction.

Table 2

Baseline characteristics among patients diagnosed with incident heart failure in Denmark between 2003 and 2010 (N = 24504)

 N (%)
Total
24504 (100)
Age mean (SD)
70.8 (13.2)
Gender
 
Male
15607 (63.7)
Female
8897 (36.3)
Left Ventricular Ejection Fraction (LVEF)
 
LVEF < 25
6609 (27.0)
25 ≤ LVEF ≤ 35
7803 (31.8)
35 < LVEF ≤ 40
3498 (14.3)
40 < LVEF < 50
2287 (9.3)
LVEF ≥ 50
1134 (4.6)
Missing
3173 (13.6)
New York Heart Association (NYHA) classification
 
NYHA-class 1
1912 (7.8)
NYHA-class 2
8209 (33.5)
NYHA-class 3
4462 (18.8)
NYHA-class 4
459 (1.9)
Missing
9462 (38.6)
Previous Acute Myocardial Infarction (AMI)
 
Yes
8046 (32.8)
No
14859 (60.6)
Missing
1599 (6.5)
Stroke
 
Yes
2561 (10.5)
No
19576 (79.9)
Missing
2367 (9.7)
Chronic Obstructive Pulmonary Disease (COPD)
 
Yes
3759 (15.3)
No
18480 (75.4)
Missing
2265 (9.2)
In treatment for hypertension
 
Yes
8335 (34.0)
No
14378 (58.7)
Missing
1791 (7.3)
Diabetes
 
Yes
4530 (18.5)
No
18362 (74.9)
Missing
1612 (6.6)
Alcohol intake
 
Maximum 14 drinks for women and 21 for men per week
16683 (68.1)
More than 14 drinks for women and 21 for men per week
1639 (6.7)
Missing
6010 (25.7)
Smoking habits
 
Smoker
7101 (29.0)
Non-smoker
17335 (70.8)
Missing48 (0.2)

SD Standard Deviation, LVEF Left Ventricular Ejection Fraction, NYHA New York Heart Association, AMI Acute Myocardial Infarction, COPD Chronic Obstructive Pulmonary Disease.

It was not possible to differentiate between inpatients and outpatients until 2006. Results from 2006 to 2010 are available in the supplementary online material.

Processes of care monitored in the Danish heart failure registry NYHA New York Heart Association, ACEI/ATII Angiotensin Converting Enzyme/Angiotensin II Antagonist inhibitors, LVEF Left Ventricular Ejection Fraction. Baseline characteristics among patients diagnosed with incident heart failure in Denmark between 2003 and 2010 (N = 24504) SD Standard Deviation, LVEF Left Ventricular Ejection Fraction, NYHA New York Heart Association, AMI Acute Myocardial Infarction, COPD Chronic Obstructive Pulmonary Disease. It was not possible to differentiate between inpatients and outpatients until 2006. Results from 2006 to 2010 are available in the supplementary online material. Data are registered for HF patients admitted to hospital or at the first outpatient visit as part of the clinical routine by cardiologists and nursing staff. The use of 2 processes of care (echocardiography and New York Heart Association classification (NYHA classification) and 1-year mortality is monitored in all patients. The remaining processes of care (Angiotensin Converting Enzyme/Angiotensin II antagonist (ACE/ATII) inhibitors, betablockers, physical training, and patient education) are only monitored in patients with systolic HF (LVEF ≤ 40%). Regular, structured audits are conducted on a national, regional, and local basis, and include validation of the completeness of patient registration against local hospital discharge registries and the National Registry of Patients [19]. Furthermore, every 3 months, the participating departments receive feedback data on their performance regarding the process indicators as well as unadjusted data on mortality. The feedback data are reported on a web-based information system allowing each participating hospital to review its performance data, and benchmark them against the region and the whole country.

Study population

The study population included patients with a first time hospitalization (including in- and out-patients) with HF as the primary diagnosis. Diagnoses are made by an experienced cardiologist, using the ESC guidelines for definition of HF, and recorded according to the International Classification of Diseases, 10th revision (ICD-10) (Codes: I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.8, I42.9, I50.0, I50.1, I50.2, I50.3, I50.8, I50.9). Outpatients had typically previously been admitted to a cardiology ward with acute myocardial infarction and had during the admission developed symptoms of HF. After treatment for the acute myocardial infarction, the patients were then referred to an outpatient cardiology clinic for treatment of the HF. The decision of recording a patient in the registry is always made by a senior cardiologist to ensure the validity of the HF diagnosis [7,20]. Each patient was only included once in the analyses. Patients were 18 years of age or older and Danish residents. They were enrolled irrespective of their left ventricular function. The total number of patients registered in the DHFR was 24510 in the study period, but six patients were under 18 years of age, and therefore excluded, leaving 24504 patients for analysis. A total of 41 hospitals and 54 departments were represented in this study. The hospitals and departments, which represent all hospitals and departments responsible for treating HF patients in Denmark, were identified by Danish Regions, which are responsible for running the hospitals. For the majority of the departments, the completeness of the registration of patients was 98-100% in 2010 compared with local hospital discharge registries and the Danish National Registry of Patients [16].

Data on patient characteristics and mortality

Data on patient characteristics, including gender, age, comorbidity, left ventricular ejection fraction and NYHA classification as well as alcohol intake and smoking habits, were obtained from the DHFR. Information on vital status (1-year mortality) was obtained from the Danish Civil Registration System [21], which maintains electronic records of changes in the vital status of all residents. Each record carries a unique 10-digit civil registration number, which is used in all Danish population based registries and enables unambiguous linkage among these registries. The study was approved by the Danish Data Protection Agency (J.no. 2008-41-2072), the DHFR, and the Danish Ministry of Health.

Statistics

We computed the proportion of patients receiving the individual processes of care among those eligible as well as the proportion of HF patients who died within 1 year of admission or first contact, both overall for the entire study period and according to calendar year (2003–2010). Comparisons over time were made using binary regression to compute the relative risk (RR) with 95% confidence intervals (CI) using 2003 as reference. A composite quality of care measure was also computed for each department. This measure was defined as the total number of received processes of care divided by the total number of processes of care relevant to the patients admitted to the individual department. Analyses on mortality were conducted for the entire study population and stratified according to LVEF (40% or less vs. more than 40%). For some patients, data on one or more of the covariates were missing (Table 2). We used multiple imputation to impute the missing values assuming that data was missing at random (stata command: ice) [22-24]. We created 5 datasets based on the following covariates: age, gender, left ventricular ejection fraction, previous acute myocardial infarction, stroke, chronic obstructive pulmonary disease, diabetes, alcohol intake, smoking habits and patients in treatment for hypertension. The proportion of patients, for whom data on these variables were missing, varied between 0.0%-25.7%. We compared 1-year mortality between patients from 2010 and 2003, respectively using multivariable Cox proportional hazards regression, while controlling for the patient characteristics presented in Table 2 (except for NYHA class, due to a high proportion missing data and inpatient/outpatient status, which was not registered before 2006). Data were analysed using Stata 10.0 (StataCorp LP, College Station, Texas).

Results

Processes of care

Baseline characteristics of the total patient population are presented in Table 2. In the Additional file 1: Table S1, the characteristics are listed according to year of registration (2003 to 2010). The proportion of patients receiving the individual processes of care increased substantially between 2003 and 2010 (Table 3), i.e., use of echocardiography (RR 1.45, 95% CI, 1.39-1.50), NYHA classification (RR 2.91, 95% CI, 2.69-3.14) , betablockers (RR 1.23, 95% CI 1.15-1.29), physical training (RR 4.04, 95% CI, 2.96-5.52) and patient education (RR 1.65, 95% CI, 1.52-1.80). The only exception was the use of ACE/ATII inhibitors, where no overall changes were observed (RR 1.01, 95% CI, 0.99-1.04).
Table 3

Received processes of care among patients diagnosed with incident heart failure in Denmark between 2003 and 2010 (N = 24504)

Total
Year 2003 to 2010
Year 2003
Year 2010
Crude RR (95% CI)
N (%)
N (%)
N (%)
 24504 (100)1624 (100)3809 (100) 
Processes of care
 
 
 
 
Echocardiograph performed
19419 (79.5)
1010 (62.7)
3430 (90.5)
1.45 (1.39-1.50)
NYHA classification assessed
15042 (61.6)
475 (29.4)
3237 (85.5)
2.91 (2.69-3.14)
ACE/ATII inhibitors given
12565 (93.0)
446 (92.0)
2628 (93.2)
1.01 (0.99-1.04)
Betablockers given
11272 (84.4)
350 (72.6)
2489 (88.3)
1.23 (1.15-1.29)
Physical training
2278 (15.9)
39 (5.6)
631 (22.8)
4.04 (2.96-5.52)
Patient education9852 (70.0)273 (49.3)2281 (81.4)1.65 (1.52-1.80)

NYHA New York Heart Association, ACE/ATII Angiotensin Converting Enzyme/Angiotensin II Antagonist inhibitors.

Received processes of care among patients diagnosed with incident heart failure in Denmark between 2003 and 2010 (N = 24504) NYHA New York Heart Association, ACE/ATII Angiotensin Converting Enzyme/Angiotensin II Antagonist inhibitors. Figure 1 shows the increase in the proportion of patients who received the recommended processes of care between 2003 and 2010.
Figure 1

Proportion of patients receiving the recommended processes of care among patients diagnosed with incident heart failure in Denmark 2003–2010. NYHA classification: New York Heart Association classification, ACE/ATII inhibitors: Angiotensin Converting Enzyme/ Angiotensin II antagonist inhibitor.

Proportion of patients receiving the recommended processes of care among patients diagnosed with incident heart failure in Denmark 2003–2010. NYHA classification: New York Heart Association classification, ACE/ATII inhibitors: Angiotensin Converting Enzyme/ Angiotensin II antagonist inhibitor. Figure 2 presents the overall composite process indicator, reflecting the proportion of all recommended processes of care that was delivered in 2010 at the individual departments. Although overall improvements were observed for most processes of care, substantial variation in quality of care remains among hospital departments treating patients with incident HF in Denmark. The proportion of delivered recommended processes of care varied between 50% and 89% across the departments.
Figure 2

Variation between Danish hospital departments in overall proportion of delivered processes of recommended care to patients with incident heart failure in 2010. The bars represent individual hospital departments.

Variation between Danish hospital departments in overall proportion of delivered processes of recommended care to patients with incident heart failure in 2010. The bars represent individual hospital departments.

Mortality

Overall 1-year all-cause mortality among patients registered in the DHFR decreased from 20.5% in 2003 to 12.8% in 2010 (Table 4).
Table 4

One-year mortality among patients diagnosed with incident heart failure in Denmark in 2010 vs. 2003

 
Mortality 2003
Mortality 2010
Unadjusted HR
Adjusted HR *
Adjusted HR †
 N/total (%)N/total (%)(95% CI)(95% CI)(95% CI)
Total
333/1624 (20.5)
488/3809 (12.8)
0.59 (0.51-0.67)
0.65 (0.56-0.75)
0.79 (0.65-0.96)
LVEF ≤40%
277/1379 (20.1)
408/3141 (13.0)
0.61 (0.52-0.71)
0.67 (0.57-0.78)
0.85 (0.69-1.05)
LVEF >40%56/245 (22.9)79/668 (11.8)0.47 (0.31-0.74)0.58 (0.40-0.84)0.51 (0.30-0.89)

*Hazard Ratio (HR) adjusted for age and gender.

† Hazard Ratio (HR) adjusted for the following patient characteristics: age, gender, LVEF, previous acute myocardial infarction, stroke, chronic obstructive pulmonary disease, diabetes, alcohol intake, smoking habits, and in treatment for hypertension.

LVEF Left Ventricular Ejection Fraction.

Overall and stratified according to selected patient characteristics.

One-year mortality among patients diagnosed with incident heart failure in Denmark in 2010 vs. 2003 *Hazard Ratio (HR) adjusted for age and gender. † Hazard Ratio (HR) adjusted for the following patient characteristics: age, gender, LVEF, previous acute myocardial infarction, stroke, chronic obstructive pulmonary disease, diabetes, alcohol intake, smoking habits, and in treatment for hypertension. LVEF Left Ventricular Ejection Fraction. Overall and stratified according to selected patient characteristics. The overall adjusted hazard ratio (HR) for 1-year mortality was 0.79 (95% CI, 0.65-0.96) after multivariable adjustment for patient characteristics (age, gender, LVEF, previous acute myocardial infarction, stroke, chronic obstructive pulmonary disease, diabetes, alcohol intake, smoking habits and in treatment for hypertension), when comparing patients diagnosed in 2010 with patients diagnosed in 2003. Analyses were also stratified for LVEF (Table 4). The improvements in mortality appeared to be better in patients with preserved ejection fraction compared to patients with reduced ejection fraction. The confidence intervals were, however, overlapping.

Discussion

We found that implementation of indicator monitoring for HF care in Denmark has been associated with substantial improvements in the use of guideline recommended processes of care among patients registered in the national HF registry. Similar results have been observed in at least two other major quality improvement initiatives: The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE-HF) for outpatient cardiology practices where 7 quality measures were assessed and significant improvement achieved for 5 of the measures. Identical to our study, they did not reach statistical significance in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [10]. Likewise, The Get With the Guidelines Programme for Heart Failure demonstrated better processes of care as well as improved performance over time in hospitals following the guidelines compared to hospitals that did not [18], as also shown in our study. Furthermore, we observed a reduced 1-year mortality rate among Danish HF patients included in the DHFR when comparing patients diagnosed in 2010 with patients diagnosed in 2003. Direct comparisons with other studies is somewhat hampered by the use of different study designs (population-based vs. selected institutions) and patient populations (prevalent vs. incident patients, inpatients vs. outpatients). However, the baseline profile of our patients appears to be comparable with the profile reported in a number of other studies [10,11,25,26]. Furthermore, our findings are in general in accordance with and extend findings from other existing studies, which have addressed the effects of implementation of clinical guidelines and indicator monitoring. According to two studies by Fonarow et al. based on data from OPTIMIZE-HF (The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) and IMPROVE HF (Primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting cohort), use of guideline recommended therapies, including discharge instructions, assessment of left ventricular function, ACE inhibitors or angiotensin II receptor blockers (ARBs) and betablockers at discharge, was associated with lower mortality [10,27]. There are conflicting results, though, as Heidenreich et al. found a decrease in the 30-day readmission rate, but not in the 30-day mortality rate using data from the American Heart Association’s Get With The Guidelines Program. The inconsistency may be related to the studied processes of care and outcomes. The Get With The Guidelines Program focused on documentation of LVEF, use of ACE inhibitors if LVEF was less than 40%, as well as discharge instructions and smoking cessation. A stronger association between the processes of care and short-term mortality could possibly have been found if the use of betablockers or aldosterone antagonists had also been assessed since use of these drugs has been shown to improve survival in randomized trials [18]. Our population included both patients with and without preserved ejection fraction, although it should be noted that the proportion of included patients with preserved ejection fraction was quite small (4.6%). Although we found no statistically significant difference in the improvements in mortality during the study period for patients with versus patients without preserved ejection fraction, we did observe an indication of a stronger improvement among patients with preserved ejection fraction. This is noteworthy as the existing evidence base for treatment of patients with preserved ejection fraction is weak as no treatment has yet been shown to reduce morbidity and mortality in this patient group [17]. Studies on other cardiovascular patient groups, including patients with acute coronary syndrome and stroke, have also provided evidence for the effectiveness of optimizing guideline recommended care among patients encountered in real-world clinical practice [28-31]. Our study appear to add further support to the important role of clinical guidelines and HF programmes as tools for bridging the gap between research and routine clinical practice. In the DHFR, the continuous monitoring of the quality of care is supplemented by regular audits and public reporting and release of the performance data from the individual departments. Such steps may further ensure commitment and active involvement of the stakeholders, including clinicians, administrators, patients and politicians. However, challenges remain as demonstrated by the substantial variation between the hospital departments in the overall quality of care even after years of monitoring and auditing.

Strengths and limitations

The strengths of our study include the prospective nationwide population-based design and the large number of patients included, as well as the fact that registration is mandatory to all hospitals in Denmark treating patients with HF, keeping in mind that not all hospitals were capable of beginning registration at the same time. In addition, thorough efforts are made to ensure data validity in the DNIP. Regular multidisciplinary structured audits are conducted, which include validation of the completeness of patient registration against hospital discharge registries and discussion and exchange of experience and knowledge in order to explain the results and implement improvements [15]. The main limitation is the observational nature of our study, which precludes firm conclusions about causality, in particular with regards to the findings on mortality. The completeness of the registration of a patient is important in this context and it should therefore be noted that the number of patients included in DHFR per year clearly increased during the study period (from 1624 patients in 2003 to 3809 patients in 2010). This reflected an increasing completeness of the DHFR as all relevant hospitals and departments began reporting to the registry at some point between 2003 and 2010. The DHFR aims to include all incident patients admitted with HF as the primary diagnosis. Consequently, the DHFR will not reflect the incidence of HF in the general Danish population. The low proportion of patients with preserved ejection fraction (4.6%) also indicates that not all hospitalized HF patients were included since it has been estimated that as many as 20% to 60% of HF patients have a normal or near normal LVEF [8]. However, the high completeness of the DHFR compared with hospital discharge registries, indicates that the registry probably did cover the vast majority of incident HF patients admitted to Danish hospitals with HF as the primary diagnosis during the study period. Other factors, besides the nationwide initiative, may potentially have contributed to the improved quality of care and lower mortality including a major structural reform of the Danish health care system in 2007 and a generally increased awareness among clinicians of guideline recommendations and in particular increased focus on caring for persons with chronic conditions. The latter has during the study period been specifically stimulated by reports from the National Board of Health presenting different options for improving care for those with chronic conditions as well as the publication of disease management programs for persons with chronic conditions [32,33]. Changes over time in the prognostic profile of the patients with incident HF, e.g., the increase in the proportion of patients being treated as outpatients, is another important issue. Although we controlled for a range of well-established prognostic factors in the analyses on changes in mortality over time, data was not available on all relevant factors (e.g., creatinine levels and use of implantable cardioverter defibrillators, cardiac resynchronization therapy, and aldosterone antagonist medications). In addition, the proportion of patients for whom data were missing was substantial for some of the registered variables, e.g., NYHA class (38.6%). Assuming that our data were missing at random, we used multiple imputation to account for missing data on the covariates included in the multivariable analyses on mortality. This approach is not without pitfalls, in particular due to the difficulties with assessing whether data are truly missing at random. However, the implications of using the technique appeared modest in the analyses, as all analyses indicated a lower mortality among patients diagnosed in 2010 patients compared with patients diagnosed in 2003 patients independently on how the available covariates were included in the multivariable analyses (data not shown). Finally, the inherent risk of gaming in top-down initiated quality improvement initiatives such as the DHFR should not be forgotten. “Gaming” is here understood as reactive subversion such as “hitting the target and missing the point” or reducing performance where targets do not apply. The phenomenon is described by the economist Charles Goodhart, who following the failure of the UK government’s reliance on money supply targets in the 1980s to control inflation, to stated: “Any observed statistical regularity will tend to collapse once pressure is placed on it for control purposes’ because actors will change their conduct when they know that the data they produce will be used to control them” (Goodhart [34], p. 96). However, the risk of gaming in the DHFR was probably quite low due to the regular national, regional and local multidisciplinary clinical audits, where data collection and performance was discussed in details. Furthermore, the data validity was also ensured by multiple audits of medical journals and consistently updated manuals with explicit instructions to the staff involved in data collection.

Conclusions

In conclusion, use of guideline recommended processes of care has improved substantially between 2003 and 2010 following the initiation of systematic quality of care monitoring among incident HF patients admitted to Danish hospitals and registered in the DHFR. The 1-year mortality appear to have decreased during the same period.

Competing interest

The authors declare that they have no competing interest.

Authors’ contributions

AN, SPJ, MLS and KE designed the study. AN was the principal investigator and lead author in the analysis of the data and wrote the draft of the manuscript. All authors participated in the interpretation of the findings. All authors took part in reviewing and editing the manuscript and approved the final version to be published.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1472-6963/13/391/prepub

Additional file 1: Table S1

Baseline characteristics of 24504 incident heart failure patients in Denmark registered in the Danish National Indicator Project between 2003 and 2010, and each separate year from 2003 to 2010. Click here for file
  32 in total

1.  ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America.

Authors:  Robert O Bonow; Susan Bennett; Donald E Casey; Theodore G Ganiats; Mark A Hlatky; Marvin A Konstam; Costas T Lambrew; Sharon-Lise T Normand; Ileana L Piña; Martha J Radford; Andrew L Smith; Lynne Warner Stevenson; Robert O Bonow; Susan J Bennett; Gregory Burke; Kim A Eagle; Harlan M Krumholz; Costas T Lambrew; Jane Linderbaum; Frederick A Masoudi; Sharon-Lise T Normand; James L Ritchie; John S Rumsfeld; John A Spertus
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

2.  Quality of care and mortality among patients with stroke: a nationwide follow-up study.

Authors:  Annette Ingeman; Lars Pedersen; Heidi H Hundborg; Palle Petersen; Susanne Zielke; Jan Mainz; Paul Bartels; Søren P Johnsen
Journal:  Med Care       Date:  2008-01       Impact factor: 2.983

3.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

Review 4.  Improving quality of care and outcomes for heart failure. -Role of registries-.

Authors:  Gregg C Fonarow
Journal:  Circ J       Date:  2011-07-05       Impact factor: 2.993

5.  The Danish National Hospital Register. A valuable source of data for modern health sciences.

Authors:  T F Andersen; M Madsen; J Jørgensen; L Mellemkjoer; J H Olsen
Journal:  Dan Med Bull       Date:  1999-06

6.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.

Authors:  Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen
Journal:  Eur Heart J       Date:  2005-04-12       Impact factor: 29.983

7.  Survival of patients with a new diagnosis of heart failure: a population based study.

Authors:  M R Cowie; D A Wood; A J Coats; S G Thompson; V Suresh; P A Poole-Wilson; G C Sutton
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

8.  Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.

Authors:  Tomas Jernberg; Per Johanson; Claes Held; Bodil Svennblad; Johan Lindbäck; Lars Wallentin
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

9.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

Authors:  Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter
Journal:  BMJ       Date:  2009-06-29

Review 10.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

View more
  10 in total

1.  How to best assess quality of drug treatment in patients with heart failure.

Authors:  Ramin Zarrinkoub; Thomas Kahan; Sven-Erik Johansson; Per Wändell; Märit Mejhert; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2016-04-11       Impact factor: 2.953

2.  Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation - Results from the German EuroAspire IV cohort.

Authors:  Caroline Morbach; Martin Wagner; Stefan Güntner; Carolin Malsch; Mehmet Oezkur; David Wood; Kornelia Kotseva; Rainer Leyh; Georg Ertl; Wolfgang Karmann; Peter U Heuschmann; Stefan Störk
Journal:  BMC Cardiovasc Disord       Date:  2017-05-05       Impact factor: 2.298

3.  Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).

Authors:  Thomas Dieterle; Stefan Schaefer; Ina Meyer; Gabriele Ackermann; Kashan Ahmed; Roger Hullin
Journal:  ESC Heart Fail       Date:  2020-05-05

4.  Benchmarking Danish hospitals on mortality and readmission rates after cardiovascular admission.

Authors:  Greg Ridgeway; Mette Nørgaard; Thomas Bøjer Rasmussen; William D Finkle; Lars Pedersen; Hans Erik Bøtker; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2019-01-04       Impact factor: 4.790

5.  Burden of heart failure in Flemish general practices: a registry-based study in the Intego database.

Authors:  Miek Smeets; Bert Vaes; Pavlos Mamouris; Marjan Van Den Akker; Gijs Van Pottelbergh; Geert Goderis; Stefan Janssens; Bert Aertgeerts; Séverine Henrard
Journal:  BMJ Open       Date:  2019-01-07       Impact factor: 2.692

6.  Development of the International Cardiac Rehabilitation Registry Including Variable Selection and Definition Process.

Authors:  Mohiul I Chowdhury; Karam Turk-Adawi; Abraham Samuel Babu; Gabriela Lime de Melo Ghisi; Pamela Seron; Tee Joo Yeo; Jamal Uddin; Martin Heine; Marianna Garcia Saldivia; Evangelia Kouidi; Masoumeh Sadeghi; Raghdah Aljehani; Sherry L Grace
Journal:  Glob Heart       Date:  2022-01-11

Review 7.  The Danish Heart Failure Registry.

Authors:  Inge Schjødt; Anne Nakano; Kenneth Egstrup; Charlotte Cerqueira
Journal:  Clin Epidemiol       Date:  2016-10-25       Impact factor: 4.790

8.  The role of the clinical departments for understanding patient heterogeneity in one-year mortality after a diagnosis of heart failure: A multilevel analysis of individual heterogeneity for profiling provider outcomes.

Authors:  Nermin Ghith; Anne Frølich; Juan Merlo
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

9.  Mortality Risk Among Heart Failure Patients With Depression: A Nationwide Population-Based Cohort Study.

Authors:  Kasper Adelborg; Morten Schmidt; Jens Sundbøll; Lars Pedersen; Poul Videbech; Hans Erik Bøtker; Kenneth Egstrup; Henrik Toft Sørensen
Journal:  J Am Heart Assoc       Date:  2016-09-07       Impact factor: 5.501

10.  Use of histamine H2 receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study.

Authors:  Kasper Adelborg; Jens Sundbøll; Morten Schmidt; Hans Erik Bøtker; Noel S Weiss; Lars Pedersen; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2018-05-07       Impact factor: 4.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.